127 related articles for article (PubMed ID: 15138626)
1. Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines.
Murata T; Haisa M; Uetsuka H; Nobuhisa T; Ookawa T; Tabuchi Y; Shirakawa Y; Yamatsuji T; Matsuoka J; Nishiyama M; Tanaka N; Naomoto Y
Int J Mol Med; 2004 Jun; 13(6):865-8. PubMed ID: 15138626
[TBL] [Abstract][Full Text] [Related]
2. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line].
Yang XK; Zheng F; Chen JH; Gao QL; Lu YP; Wang SX; Wang CY; Ma D
Ai Zheng; 2002 Dec; 21(12):1288-91. PubMed ID: 12520732
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
[TBL] [Abstract][Full Text] [Related]
5. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
6. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
7. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
[TBL] [Abstract][Full Text] [Related]
9. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
[TBL] [Abstract][Full Text] [Related]
10. [Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism].
Qin TN; Wang LL
Di Yi Jun Yi Da Xue Xue Bao; 2002 Apr; 22(4):344-6. PubMed ID: 12390742
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment.
Ikeguchi M; Nakamura S; Kaibara N
Oncol Rep; 2002; 9(5):1121-6. PubMed ID: 12168083
[TBL] [Abstract][Full Text] [Related]
14. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
[TBL] [Abstract][Full Text] [Related]
15. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
16. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
[TBL] [Abstract][Full Text] [Related]
17. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
Wang J; Liu X; Jiang W
Chin Med J (Engl); 2000 Oct; 113(10):957-60. PubMed ID: 11775848
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells.
Wang X; Masters JR; Wong YC; Lo AK; Tsao SW
Anticancer Res; 2001; 21(1A):403-8. PubMed ID: 11299769
[TBL] [Abstract][Full Text] [Related]
20. The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.
Shinagawa A; Yoshida Y; Kurokawa T; Horiuchi Y; Tsuyoshi H; Orisaka M; Sawamura Y; Kleinman HK; Kotsuji F
Int J Oncol; 2011 Dec; 39(6):1359-64. PubMed ID: 21935568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
